Peptide-Based Treatment: A Promising Cancer Therapy

Journal of Immunology Research

Volumn 2015, Issue , 2015, Pages

  Xiao, Yu Feng ^a   Jie, Meng Meng ^a   Li, Bo Sheng ^a   Hu, Chang Jiang ^a   Xie, Rui ^a   Tang, Bo ^a   Yang, Shi Ming ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; PEPTIDE; CANCER VACCINE; NANOMATERIAL; SUBUNIT VACCINE; TUMOR ANTIGEN;

BREAST CANCER; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER THERAPY; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; HUMAN; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; REVIEW; STOMACH CANCER; ANIMAL; CHEMISTRY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASMS; VACCINATION;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CYTOTOXICITY, IMMUNOLOGIC; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOTHERAPY; NANOSTRUCTURES; NEOPLASMS; PEPTIDES; VACCINATION; VACCINES, SUBUNIT;

EID: 84947093098     PISSN: 23148861     EISSN: 23147156     Source Type: Journal    
DOI: 10.1155/2015/761820     Document Type: Review

References (132)

1. N. Iikuni, B. H. Hahn, and A. La Cava, "Potential for anti-DNA immunoglobulin peptide therapy in systemic lupus erythematosus," Expert Opinion on BiologicalTherapy, vol. 9, no. 2, pp. 201-206, 2009.
2. M. Larché, "Peptide therapy for allergic diseases: basic mechanisms and new clinical approaches," Pharmacology&Therapeutics, vol. 108, no. 3, pp. 353-361, 2005.
3. L.-P. Boulet, "Allergen-derivedTcell peptides and late asthmatic responses," American Journal of Respiratory and Critical Care Medicine, vol. 169, no. 1, pp. 2-3, 2004.
4. S. P. Atamas, "Relief fromwithin: a peptide therapy for fibrosis," Science TranslationalMedicine, vol. 4, no. 136,Article ID136fs16, 2012.
5. B. Oh and M. Lee, "Combined delivery of HMGB-1 box A peptide and S1PLyase siRNA in animal models of acute lung injury," Journal of Controlled Release, vol. 175, no. 1, pp. 25-35, 2014.
6. T. Nojiri, H. Hosoda, T. Tokudome et al., "Atrial natriuretic peptide inhibits lipopolysaccharide-induced acute lung injury," Pulmonary Pharmacology & Therapeutics, vol. 29, no. 1, pp. 24-30, 2014.
7. J. N. Francis andM. Larché, "Peptide-based vaccination: where do we stand?" Current Opinion in Allergy and Clinical Immunology, vol. 5, no. 6, pp. 537-543, 2005.
8. M. A. Cheever and C. S. Higano, "PROVENGE (sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine," Clinical Cancer Research, vol. 17, no. 11, pp. 3520-3526, 2011.
9. R. Takahashi, U. Toh, N. Iwakuma et al., "Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patients," Breast Cancer Research, vol. 16, no. 4, article R70, 2014.
10. R. Roy, D. Zurakowski, J. Wischhusen et al., "Urinary TIMP-1 and MMP-2 levels detect the presence of pancreatic malignancies," British Journal of Cancer, vol. 111, no. 9, pp. 1772-1779, 2014.
11. X. B. Wang, Y. F. Li, H. M. Tian et al., "Macrophage inhibitory cytokine 1 (MIC-1/GDF15) as a novel diagnostic serum biomarker in pancreatic ductal adenocarcinoma," BMC Cancer, vol. 14, no. 1, article 578, 2014.
12. N. Jiang, R. H. Xue, F. F. Bu, X. Tong, J. K. Qiang, and R. Liu, "Decreased RGS6 expression is associated with poor prognosis in pancreatic cancer patients," International Journal of Clinical and Experimental Pathology, vol. 7, no. 7, pp. 4120-4127, 2014.
13. Z.-X. Zheng, Y. Sun, Z.-D. Bu et al., "Intestinal stem cell marker LGR5 expression during gastric carcinogenesis," World Journal of Gastroenterology, vol. 19, no. 46, pp. 8714-8721, 2013.
14. Y. Lu, B. Zhou,G.Q.Gao,D. Li, X. D. Liu, and B.Huang, "Clinical significance in combined detection of serum pepsinogen I, pepsinogen II and carbohydrate antigen 242 in gastric cancer," Hepatogastroenterology, vol. 61, no. 129, pp. 255-258, 2014.
15. S. E. Mcgrath, A. Michael, R. Morgan, and H. Pandha, "EN2: a novel prostate cancer biomarker," Biomarkers in Medicine, vol. 7, no. 6, pp. 893-901, 2013.
16. W. Li, K. Nichols, C.-A. Nathan, and Y. Zhao, "Mitochondrial uncoupling protein 2 is up-regulated in human head and neck, skin, pancreatic, and prostate tumors," Cancer Biomarkers, vol. 13, no. 5, pp. 377-383, 2013.
17. N. Boku, "HER2-positive gastric cancer," Gastric Cancer, vol. 17, no. 1, pp. 1-12, 2014.
18. J. S. Zanetti, D. F. Soave, J. P. Oliveira-Costa et al., "The role of tumor hypoxia in MUC1-positive breast carcinomas," Virchows Archiv, vol. 459, no. 4, pp. 367-375, 2011.
19. J. Albrethsen, C. H. Møller, J. Olsen, H. Raskov, and S. Gammeltoft, "Human neutrophil peptides 1, 2 and 3 are biochemical markers for metastatic colorectal cancer," European Journal of Cancer, vol. 42, no. 17, pp. 3057-3064, 2006.
20. M. Bloch, Y. Kam, E. Yavin et al., "The relative roles of charge and a recognition peptide in luminal targeting of colorectal cancer by fluorescent polyacrylamide," European Journal of Pharmaceutical Sciences, vol. 47, no. 5, pp. 904-913, 2012.
21. S. S. Comstock, D. Xu, K. Hortos et al., "Association of insulinrelated serum factors with colorectal polyp number and type in adult males," Cancer Epidemiology, Biomarkers & Prevention, vol. 23, no. 9, pp. 1843-1851, 2014.
22. W. Wang, S. Guan, S. Sun et al., "Detection of circulating antibodies to linear peptide antigens derived from ANXA1 and DDX53 in lung cancer," Tumor Biology, vol. 35, no. 5, pp. 4901-4905, 2014.
23. M. Zhang, X. Li, X. Zhang, Y. Yang, Z. Feng, and X. Liu, "Association of serum hemoglobin A1c, C-peptide and insulinlike growth factor-1 levels with the occurrence and development of lung cancer," Molecular Clinical Oncology, vol. 2, no. 4, pp. 506-508, 2014.
24. M. J. McGuire, B. P. Gray, S. Li et al., "Identification and characterization of a suite of tumor targeting peptides for nonsmall cell lung cancer," Scientific Reports, vol. 4, article 4480, 2014.
25. D. de Costa, I. Broodman,W. Calame et al., "Peptides from the variable region of specific antibodies are shared among lung cancer patients," PLoS ONE, vol. 9, no. 5, Article ID e96029, 2014.
26. A.Wang, L.Chen, K. Pu, and Y. Zhu, "Identification of stem-like cells in non-small cell lung cancer cells with specific peptides," Cancer Letters, vol. 351, no. 1, pp. 100-107, 2014.
27. S. Nishida, S. Koido, Y. Takeda et al., "Wilms tumor gene (WT1) peptide-based cancer vaccine combined with gemcitabine for patients with advanced pancreatic cancer," Journal of Immunotherapy, vol. 37, no. 2, pp. 105-114, 2014.
28. N. Suzuki, S. Hazama, T. Ueno et al., "A phase i clinical trial of vaccination with KIF20A-derived peptide in combination with gemcitabine for patients with advanced pancreatic cancer," Journal of Immunotherapy, vol. 37, no. 1, pp. 36-42, 2014.
29. C. Staff, F.Mozaffari, J.-E. Frodin, H.Mellstedt, andM. Liljefors, "Telomerase (GV1001) vaccination together with gemcitabine in advanced pancreatic cancer patients," International Journal of Oncology, vol. 45, no. 3, pp. 1293-1303, 2014.
30. T. Masuzawa, Y. Fujiwara, K. Okada et al., "Phase I/II study of S-1 plus cisplatin combined with peptide vaccines for human vascular endothelial growth factor receptor 1 and 2 in patients with advanced gastric cancer," International Journal ofOncology, vol. 41, no. 4, pp. 1297-1304, 2012.
31. H. Ishikawa, M. Imano, O. Shiraishi et al., "Phase I clinical trial of vaccination with LY6K-derived peptide in patients with advanced gastric cancer," Gastric Cancer, vol. 17, no. 1, pp. 173-180, 2014.
32. J.M. S. Saif, J. Vadakekolathu, S. S. Rane et al., "Novel prostate acid phosphatase-based peptide vaccination strategy induces antigen-specific T-cell responses and limits tumour growth in mice," European Journal of Immunology, vol. 44, no. 4, pp. 994-1004, 2014.
33. M.Mansourian, A. Badiee, S. A. Jalali et al., "Effective induction of anti-tumor immunity using p5 HER-2/neu derived peptide encapsulated in fusogenic DOTAP cationic liposomes coadministrated with CpG-ODN," Immunology Letters, vol. 162, no. 1, part A, pp. 87-93, 2014.
34. J. Ohtake, T. Ohkuri, Y. Togashi, H. Kitamura, K. Okuno, and T. Nishimura, "Identification of novel helper epitope peptides of Survivin cancer-associated antigen applicable to developing helper/killer-hybrid epitope long peptide cancer vaccine," Immunology Letters, vol. 161, no. 1, pp. 20-30, 2014.
35. E. A. Mittendorf, G. T. Clifton, J. P. Holmes et al., "Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in highrisk breast cancer patients," Annals ofOncology, vol. 25,no. 9, pp. 1735-1742, 2014.
36. E. Y. Gil, U. H. Jo, H. J. Lee et al., "Vaccination with ErbB-2 peptides prevents cancer stem cell expansion and suppresses the development of spontaneous tumors in MMTV-PyMT transgenic mice," BreastCancer Research and Treatment, vol. 147, no. 1, pp. 69-80, 2014.
37. A. Serafino, N.Moroni, R. Psaila et al., "Anti-proliferative effect of atrial natriuretic peptide on colorectal cancer cells: evidence for an Akt-mediated cross-talk between NHE-1 activity and Wnt/β-catenin signaling," Biochimica et Biophysica Acta - Molecular Basis of Disease, vol. 1822, no. 6, pp. 1004-1018, 2012.
38. Z. J. Li, W. K. K. Wu, S. S. M. Ng et al., "A novel peptide specifically targeting the vasculature of orthotopic colorectal cancer for imaging detection and drug delivery," Journal of Controlled Release, vol. 148, no. 3, pp. 292-302, 2010.
39. C. Wang, M. Zhao, Y.-R. Liu et al., "Suppression of colorectal cancer subcutaneous xenograft and experimental lung metastasis using nanoparticle-mediated drug delivery to tumor neovasculature," Biomaterials, vol. 35,no. 4, pp. 1215-1226, 2014.
40. H. Takahashi, M. Okamoto, S. Shimodaira et al., "Impact of dendritic cell vaccines pulsed with Wilms' tumour-1 peptide antigen on the survival of patients with advanced non-small cell lung cancers," European Journal of Cancer, vol. 49, no. 4, pp. 852-859, 2013.
41. A. Kotsakis, E. Papadimitraki, E. K. Vetsika et al., "A phase II trial evaluating the clinical and immunologic response of HLA-A2+ non-small cell lung cancer patients vaccinated with an hTERT cryptic peptide," Lung Cancer, vol. 86, no. 1, pp. 59-66, 2014.
42. A. Ahsa, S. G. Ramanand, I. L. Bergin et al., "Efficacy of an EGFR-specific peptide against EGFR-dependent cancer cell lines and tumor xenografts," Neoplasia, vol. 16,no. 2, pp. 105-114, 2014.
43. A. B. Sigalov, "A novel ligand-independent peptide inhibitor of TREM-1 suppresses tumor growth in human lung cancer xenografts and prolongs survival of mice with lipopolysaccharide-induced septic shock," International Immunopharmacology, vol. 21, no. 1, pp. 208-219, 2014.
44. C. Chittasupho, K. Lirdprapamongkol, P. Kewsuwan, and N. Sarisuta, "Targeted delivery of doxorubicin to A549 lung cancer cells by CXCR4 antagonist conjugated PLGA nanoparticles," European Journal of Pharmaceutics and Biopharmaceutics, vol. 88, no. 2, pp. 529-538, 2014.
45. X. Wang, C. Yang, Y. Zhang, X. Zhen, W. Wu, and X. Jiang, "Delivery of platinum(IV) drug to subcutaneous tumor and lung metastasis using bradykinin-potentiating peptidedecorated chitosan nanoparticles," Biomaterials, vol. 35, no. 24, pp. 6439-6453, 2014.
46. Y. Y. Guan, X. Luan, J. R. Xu et al., "Selective eradication of tumor vascular pericytes by peptide-conjugated nanoparticles for antiangiogenic therapy of melanoma lung metastasis," Biomaterials, vol. 35, no. 9, pp. 3060-3070, 2014.
47. M. Noguchi, F.Moriya, S. Suekane et al., "A phase II trial of personalized peptide vaccination in castration-resistant prostate cancer patients: prolongation of prostate-specific antigen doubling time," BMC Cancer, vol. 13, article 613, 2013.
48. D. Fenoglio, P. Traverso, A. Parodi et al., "Amulti-peptide, dualadjuvant telomerase vaccine (GX301) is highly immunogenic in patients with prostate and renal cancer," Cancer Immunology, Immunotherapy, vol. 62, no. 6, pp. 1041-1052, 2013.
49. S. Shariat, A. Badiee, M. R. Jaafari, and S. A. Mortazavi, "Optimization of a method to prepare liposomes containing HER2/Neu-derived peptide as a vaccine delivery system for breast cancer," Iranian Journal of Pharmaceutical Research, vol. 13, pp. 15-25, 2014.
50. D. A. L. Vital, E. G. de Mejía, V. P. Dia, and G. Loarca-Piña, "Peptides in common bean fractions inhibit human colorectal cancer cells," Food Chemistry, vol. 157, pp. 347-355, 2014.
51. S. Inoda, R. Morita, Y. Hirohashi et al., "The feasibility of Cep55/c10orf3 derived peptide vaccine therapy for colorectal carcinoma," Experimental and Molecular Pathology, vol. 90, no. 1, pp. 55-60, 2011.
52. S. Hazama, H. Takenouchi, R. Tsunedomi et al., "Predictive biomarkers for the outcome of vaccination of five therapeutic epitope peptides for colorectal cancer," Anticancer Research, vol. 34, no. 8, pp. 4201-4205, 2014.
53. K. Okuno, F. Sugiura, K. Inoue, and Y. Sukegawa, "Clinical trial of a 7-peptide cocktail vaccine with oral chemotherapy for patients with metastatic colorectal cancer," Anticancer Research, vol. 34, no. 6, pp. 3045-3052, 2014.
54. S. J. Rayaprolu, N. S. Hettiarachchy, P. Chen, A. Kannan, and A. Mauromostakos, "Peptides derived from high oleic acid soybean meals inhibit colon, liver and lung cancer cell growth," Food Research International, vol. 50, no. 1, pp. 282-288, 2013.
55. J.M. Conlon, M. Prajeep, M. Mechkarska et al., "Peptides with in vitro anti-tumor activity from the venom of the Eastern green mamba, Dendroaspis angusticeps (Elapidae)," Journal of Venom Research, vol. 5, pp. 16-21, 2014.
56. R. E. Schoen, "The case for population-based screening for colorectal cancer," Nature Reviews Cancer, vol. 2, no. 1, pp. 65-70, 2002.
57. S. Hazama, Y. Nakamura, H. Takenouchi et al., "A phase I study of combination vaccine treatment of five therapeutic epitopepeptides for metastatic colorectal cancer; safety, immunological response, and clinical outcome," Journal of Translational Medicine, vol. 12, no. 1, article 63, 2014.
58. A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward, and D. Forman, "Global cancer statistics," CA: A Cancer Journal for Clinicians, vol. 61, no. 2, pp. 69-90, 2011.
59. M. Früh, D. de Ruysscher, S. Popat, L. Crinò, S. Peters, and E. Felip, "Small-cell lung cancer (SCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up," Annals of Oncology, vol. 24, supplement 6, pp. vi99-vi105, 2013.
60. T. J.McDonald, M. A. Ghatei, S. R. Bloom et al., "A qualitative comparison of canine plasma gastroenteropancreatic hormone responses to bombesin and the porcine gastrin-releasing peptide (GRP)," Regulatory Peptides, vol. 2, no. 5, pp. 293-304, 1981.
61. E.Gniazdowska, P. Kózmínski, K. Bánkowski, and P.Ochman, " 99mTc-labeled vasopressin peptide as a radiopharmaceutical for small-cell lung cancer (SCLC) diagnosis," Journal of Medicinal Chemistry, vol. 57, no. 14, pp. 5986-5994, 2014.
62. Z. H. Hong, Y. Z. Shi, Z. L. Liu, X. L. Zhou, Y. Yang, and J. Tang, "Preliminary radioimmunoimaging and biodistribution of 131iodine-labeled single-chain antibody fragment against progastrin-releasing peptide (31-98) in small cell lung cancer xenografts," Chinese Medical Journal, vol. 127, no. 11, pp. 2007-2011, 2014.
63. R. Siegel, J. Ma, Z. Zou, and A. Jemal, "Cancer statistics, 2014," CA: A Cancer Journal for Clinicians, vol. 64,no. 1, pp. 9-29, 2014.
64. A. Takahara, S. Koido, M. Ito et al., "Gemcitabine enhances Wilms' tumor geneWT1 expression and sensitizes human pancreatic cancer cells with WT1-speciWc T-cell-mediated antitumor immune response," Cancer Immunology, Immunotherapy, vol. 60, no. 9, pp. 1289-1297, 2011.
65. M. L. Rothenberg, M. J. Moore, M. C. Cripps et al., "A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer," Annals of Oncology, vol. 7, no. 4, pp. 347-353, 1996.
66. G. Parmiani, C. Castelli, P. Dalerba et al., "Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?" Journal of the National Cancer Institute, vol. 94, no. 11, pp. 805-818, 2002.
67. F. M. Marincola, E. M. Jaffee, D. J. Hicklin, and S. Ferrone, "Escape of human solid tumors fromT-cell recognition:molecular mechanisms and functional significance," Advances in Immunology, vol. 74, pp. 181-273, 2000.
68. L. Gao, I. Bellantuono, A. Elsässer et al., "Selective elimination of leukemic CD34+ progenitor cells by cytotoxic T lymphocytes specific forWT1," Blood, vol. 95, no. 7, pp. 2198-2203, 2000.
69. A. M. Storniolo, S. R. Allerheiligen, and H. L. Pearce, "Preclinical, pharmacologic, and phase I studies of gemcitabine," Seminars in Oncology, vol. 24,no. 2, supplement 7, pp. S7-2-S7-7, 1997.
70. A. K. Nowak, B.W. S. Robinson, and R. A. Lake, "Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy," Cancer Research, vol. 62, no. 8, pp. 2353-2358, 2002.
71. L. Rettig, S. Seidenberg, I. Parvanova, P. Samaras, A. Knuth, and S. Pascolo, "Gemcitabine depletes regulatory T-cells in human and mice and enhances triggering of vaccine-specific cytotoxic T-cells," International Journal of Cancer, vol. 129, no. 4, pp. 832-838, 2011.
72. A. K. Nowak, R. A. Lake, A. L. Marzo et al., "Induction of tumor cell apoptosis in vivo increases tumor antigen crosspresentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells," The Journal of Immunology, vol. 170, no. 10, pp. 4905-4913, 2003.
73. R. Ramakrishnan, D. Assudani, S. Nagaraj et al., "Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice,"The Journal of Clinical Investigation, vol. 120, no. 4, pp. 1111-1124, 2010.
74. E. Kawakami, R. S. Machado, S. K. Ogata, and M. Langner, "Decrease in prevalence of Helicobacter pylori infection during a 10-year period in Brazilian children," Arquivos de Gastroenterologia, vol. 45, no. 2, pp. 147-151, 2008.
75. A. Ohtsu, "Current status and future prospects of chemotherapy formetastatic gastric cancer: a review," GastricCancer, vol. 8, no. 2, pp. 95-102, 2005.
76. M. Clauss, "Molecular biology of the VEGF and the VEGF receptor family," Seminars in Thrombosis and Hemostasis, vol. 26, no. 5, pp. 561-569, 2000.
77. H. Ishizaki, T. Tsunoda, S. Wada, M. Yamauchi, M. Shibuya, andH. Tahara, "Inhibition of tumor growthwith antiangiogenic cancer vaccine using epitope peptides derived from human vascular endothelial growth factor receptor 1," Clinical Cancer Research, vol. 12, no. 19, pp. 5841-5849, 2006.
78. M. Prewett, J. Huber, Y. Li et al., "Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors," Cancer Research, vol. 59, no. 20, pp. 5209-5218, 1999.
79. N. Ferrara, H.-P.Gerber, and J. LeCouter, "Thebiology ofVEGF and its receptors," Nature Medicine, vol. 9, no. 6, pp. 669-676, 2003.
80. B. Zhang, Z. Zhang, X. Zhang, X. Gao, K. H. Kernstine, and L. Zhong, "Serological antibodies against LY6K as a diagnostic biomarker in esophageal squamous cell carcinoma," Biomarkers, vol. 17, no. 4, pp. 372-378, 2012.
81. N. Ishikawa, A. Takano, W. Yasui et al., "Cancer-testis antigen lymphocyte antigen 6 complex locus K is a serologic biomarker and a therapeutic target for lung and esophageal carcinomas," Cancer Research, vol. 67, no. 24, pp. 11601-11611, 2007.
82. M. Iwahashi,M. Katsuda,M.Nakamori et al., "Vaccination with peptides derived from cancer-testis antigens in combination with CpG-7909 elicits strong specific CD8+ T cell response in patients with metastatic esophageal squamous cell carcinoma," Cancer Science, vol. 101, no. 12, pp. 2510-2517, 2010.
83. A. L. Potosky, B. A. Miller, P. C. Albertsen, and B. S. Kramer, "The role of increasing detection in the rising incidence of prostate cancer," The Journal of the American Medical Association, vol. 273, no. 7, pp. 548-552, 1995.
84. E. S. Antonarakis and M. A. Eisenberger, "Expanding treatment options formetastatic prostate cancer,"TheNewEngland Journal of Medicine, vol. 364, no. 21, pp. 2055-2058, 2011.
85. P. W. Kantoff, C. S. Higano, N. D. Shore et al., "Sipuleucel-T immunotherapy for castration-resistant prostate cancer," The New England Journal of Medicine, vol. 363, no. 5, pp. 411-422, 2010.
86. K. Itoh and A. Yamada, "Personalized peptide vaccines: a new therapeutic modality for cancer," Cancer Science, vol. 97, no. 10, pp. 970-976, 2006.
87. T. Sasada, A. Yamada, M. Noguchi, and K. Itoh, "Personalized peptide vaccine for treatment of advanced cancer," Current Medicinal Chemistry, vol. 21, no. 21, pp. 2332-2345, 2014.
88. T. Sasada, M. Noguchi, A. Yamada, and K. Itoh, "Personalized peptide vaccination: a novel immunotherapeutic approach for advanced cancer," Human Vaccines & Immunotherapeutics, vol. 8, no. 9, pp. 1309-1313, 2012.
89. A. Yamada, T. Sasada, M. Noguchi, and K. Itoh, "Nextgeneration peptide vaccines for advanced cancer," Cancer Science, vol. 104, no. 1, pp. 15-21, 2013.
90. F. M. Speetjens, P. J. K. Kuppen,M. J. P.Welters et al., "Induction of p53-specific immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancer," Clinical Cancer Research, vol. 15, no. 3, pp. 1086-1095, 2009.
91. R. L. Metheringham, V. A. Pudney, B. Gunn, M. Towey, I. Spendlove, and L. G. Durrant, "Antibodies designed as effective cancer vaccines," mAbs, vol. 1, no. 1, pp. 71-85, 2009.
92. L. G. Durrant, V. A. Pudney, and I. Spendlove, "Using monoclonal antibodies to stimulate antitumor cellular immunity," Expert Review of Vaccines, vol. 10, no. 7, pp. 1093-1106, 2011.
93. C. A. Parise and V. Caggiano, "Disparities in race/ethnicity and socioeconomic status: risk ofmortality of breast cancer patients in theCaliforniaCancer Registry, 2000-2010,"BMCCancer, vol. 13, article 449, 2013.
94. C. Desantis, J. Ma, L. Bryan, and A. Jemal, "Breast cancer statistics, 2013," CA: A Cancer Journal for Clinicians, vol. 64, no. 1, pp. 52-62, 2014.
95. E. Mohit, A. Hashemi, and M. Allahyari, "Breast cancer immunotherapy: monoclonal antibodies and peptide-based vaccines," Expert Review of Clinical Immunology, vol. 10, no. 7, pp. 927-961, 2014.
96. S. E.Wright, "Immunotherapy of breast cancer," Expert Opinion on Biological Therapy, vol. 12, no. 4, pp. 479-490, 2012.
97. S. Dhillon, "Trastuzumab emtansine: a review of its use in patients with her2-positive advanced breast cancer previously treated with trastuzumab-based therapy," Drugs, vol. 74, no. 6, pp. 675-686, 2014.
98. L. Amiri-Kordestani, G. M. Blumenthal, Q. C. Xu et al., "FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer," Clinical Cancer Research, vol. 20, no. 17, pp. 4436-4441, 2014.
99. L. Novellino, C. Castelli, and G. Parmiani, "A listing of human tumor antigens recognized by T cells: March 2004 update," Cancer Immunology, Immunotherapy, vol. 54, no. 3, pp. 187-207, 2005.
100. G. J. Morris, S. Naidu, A. K. Topham et al., "Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the national cancer institute's surveillance, epidemiology, and end results database," Cancer, vol. 110, no. 4, pp. 876-884, 2007.
101. B. D. Lehmann, J. A. Bauer, X. Chen et al., "Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies," The Journal of Clinical Investigation, vol. 121, no. 7, pp. 2750-2767, 2011.
102. C.Wang, Y. Zhuang, Y. Zhang et al., "Toll-like receptor 3 agonist complexed with cationic liposome augments vaccine-elicited antitumor immunity by enhancing TLR3-IRF3 signaling and type I interferons in dendritic cells," Vaccine, vol. 30, no. 32, pp. 4790-4799, 2012.
103. W. Yan, W. Chen, and L. Huang, "Mechanism of adjuvant activity of cationic liposome: phosphorylation of aMAP kinase, ERK and induction of chemokines,"Molecular Immunology, vol. 44, no. 15, pp. 3672-3681, 2007.
104. M. Karkada, N. L. Berinstein, and M. Mansour, "Therapeutic vaccines and cancer: focus on DPX-0907," Biologics: Targets and Therapy, vol. 8, pp. 27-38, 2014.
105. D.Hanahan andR.A.Weinberg, "The hallmarks of cancer," Cell, vol. 100, no. 1, pp. 57-70, 2000.
106. S. K. Bhutia and T. K. Maiti, "Targeting tumors with peptides from natural sources," Trends in Biotechnology, vol. 26, no. 4, pp. 210-217, 2008.
107. K. Fernald and M. Kurokawa, "Evading apoptosis in cancer," Trends in Cell Biology, vol. 23, no. 12, pp. 620-633, 2013.
108. W. Huang, J. Seo, S. B. Willingham et al., "Learning from host defense peptides: cationic, amphipathic peptoids with potent anticancer activity," PLoS ONE, vol. 9, no. 2, Article ID e90397, 2014.
109. D. Amit and A. Hochberg, "Development of targeted therapy for bladder cancer mediated by a double promoter plasmid expressing diphtheria toxin under the control of H19 and IGF2-P4 regulatory sequences," Journal of TranslationalMedicine, vol. 8, article 134, 2010.
110. D. D.Wu, Y. F. Gao, Y. M. Qi, L. X. Chen, Y. F. Ma, and Y. Z. Li, "Peptide-based cancer therapy: opportunity and challenge," Cancer Letters, vol. 351, no. 1, pp. 13-22, 2014.
111. M. Trepel, R. Pasqualini, andW. Arap, "Screening phage-display Peptide libraries for vascular targeted peptides," in Methods in Enzymology, vol. 445 of Angiogenesis: In Vivo Systems, Part B, chapter 4, pp. 83-106, Elsevier, 2008.
112. N.D'Onofrio, M.Caraglia,A.Grimaldi et al., "Vascular-homing peptides for targeted drug delivery and molecular imaging: meeting the clinical challenges," Biochimica et BiophysicaActa - Reviews on Cancer, vol. 1846, no. 1, pp. 1-12, 2014.
113. M. Shadidi and M. Sioud, "Selective targeting of cancer cells using synthetic peptides," Drug Resistance Updates, vol. 6, no. 6, pp. 363-371, 2003.
114. S. M. Farkhani, A. Valizadeh, H. Karami, S. Mohammadi, N. Sohrabi, and F. Badrzadeh, "Cell penetrating peptides: efficient vectors for delivery of nanoparticles, nanocarriers, therapeutic and diagnostic molecules," Peptides, vol. 57, pp. 78-94, 2014.
115. A. Bolhassani, "Potential efficacy of cell-penetrating peptides for nucleic acid and drug delivery in cancer," Biochimica et Biophysica Acta - Reviews on Cancer, vol. 1816, no. 2, pp. 232-246, 2011.
116. F.-S. Kao, Y.-R. Pan, R.-Q. Hsu, and H.-M. Chen, "Efficacy verification and microscopic observations of an anticancer peptide, CB1a, on single lung cancer cell," Biochimica et Biophysica Acta - Biomembranes, vol. 1818, no. 12, pp. 2927-2935, 2012.
117. K. Beck, J. E. Gambee, C. A. Bohan, and H. P. Bächinger, "The C-terminal domain of cartilage matrix protein assembles into a triple-stranded α-helical coiled-coil structure," Journal of Molecular Biology, vol. 256, no. 5, pp. 909-923, 1996.
118. L. Q. Liu and Y. B. Miao, "Metastatic melanoma targeting property of a novel Tc-99m-labeled HYNIC-conjugated lactam bridge-cyclized alpha-MSH peptide," Nuclear Medicine and Biology, vol. 41, no. 7, p. 622, 2014.
119. F. E. González, M. Ramírez, E. B. Allerbring et al., "Melanocortin 1 receptor-derived peptides are efficiently recognized by cytotoxic T lymphocytes from melanoma patients," Immunobiology, vol. 219, no. 3, pp. 189-197, 2014.
120. E. Vacas, A. M. Bajo, A. V. Schally, M. Sánchez-Chapado, J. C. Prieto, and M. J. Carmena, "Vasoactive intestinal peptide induces oxidative stress and suppresses metastatic potential in human clear cell renal cell carcinoma," Molecular and Cellular Endocrinology, vol. 365, no. 2, pp. 212-222, 2013.
121. K. Yoshimura, T. Minami, M. Nozawa, and H. Uemura, "Phase I clinical trial of human vascular endothelial growth factor receptor 1 peptide vaccines for patients with metastatic renal cell carcinoma," British Journal of Cancer, vol. 108, no. 6, pp. 1260-1266, 2013.
122. S. Rausch, S. Kruck, A. Stenzl, and J. Bedke, "IMA901 for metastatic renal cell carcinoma in the context of new approaches to immunotherapy," Future Oncology, vol. 10, no. 6, pp. 937-948, 2014.
123. Y. Liu, X. Cui, Y.-E. Sun et al., "Intrathecal injection of the peptide Myr-NR2B9c attenuates bone cancer pain via perturbing N-methyl-D-aspartate receptor-PSD-95 protein interactions in mice," Anesthesia & Analgesia, vol. 118, no. 6, pp. 1345-1354, 2014.
124. Z. Xu, S. Ramishetti, Y.-C. Tseng, S. Guo, Y. Wang, and L. Huang, "Multifunctional nanoparticles co-delivering Trp2 peptide and CpG adjuvant induce potent cytotoxic T-lymphocyte response against melanoma and its lung metastasis," Journal of Controlled Release, vol. 172, no. 1, pp. 259-265, 2013.
125. Z. J. Li and C. H. Cho, "Peptides as targeting probes against tumor vasculature for diagnosis and drug delivery," Journal of Translational Medicine, vol. 10, article S1, 2012.
126. E. Ruoslahti, S. N. Bhatia, and M. J. Sailor, "Targeting of drugs and nanoparticles to tumors,"The Journal of Cell Biology, vol. 188, no. 6, pp. 759-768, 2010.
127. J. Enbäck and P. Laakkonen, "Tumour-homing peptides: tools for targeting, imaging and destruction," Biochemical Society Transactions, vol. 35, no. 4, pp. 780-783, 2007.
128. A. J. T. George, L. Lee, and C. Pitzalis, "Isolating ligands specific for human vasculature using in vivo phage selection," Trends in Biotechnology, vol. 21, no. 5, pp. 199-203, 2003.
129. F. Aranda, E. Vacchelli, A. Eggermont et al., "Trial watch: peptide vaccines in cancer therapy," OncoImmunology, vol. 2, no. 12, Article ID e26621, 2013.
130. M. Mohme, M. C. Neidert, L. Regli, M. Weller, and R. Martin, "Immunological challenges for peptide-based immunotherapy in glioblastoma," Cancer Treatment Reviews, vol. 40, no. 2, pp. 248-258, 2014.
131. R. Takahashi, U. Toh, N. Iwakuma et al., "Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patients," Breast Cancer Research, vol. 16, no. 4, article R70, 2014.
132. D. Valmori, J.-F. Fonteneau, C. M. Lizana et al., "Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues," The Journal of Immunology, vol. 160, no. 4, pp. 1750-1758, 1998.